Evaluation of Long-term Immunological Responses Following Reduced Dose Quadrivalent Human Papillomavirus (HPV) Vaccine Schedules: A Phase II/III Clinical Trial
Phase of Trial: Phase II/III
Latest Information Update: 13 Nov 2015
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Cervical cancer; Genital warts
- Focus Pharmacodynamics
- 22 Sep 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 03 Mar 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 31 Oct 2014 New trial record